Tesamorelin's FDA Approval Is Real. So Is the Gap Between What It Proves and What People Are Claiming.

Tesamorelin has the strongest regulatory file of any peptide in this space. The question is whether that approval proves what the longevity market thinks it proves.

In one 26-week trial, tesamorelin cut visceral fat, the deep fat packed around your organs, by 15.2%. The placebo group gained 5.0%. A 20-point swing, in six months, from one drug.

The FDA looked at that evidence and approved the drug. The Reddit threads skip who those trials enrolled: people with HIV-associated lipodystrophy, a disease that scrambles how the body stores fat. If you’re a healthy 45-year-old trying to lose belly fat, that’s not you.

Tesamorelin works. The open question is who for: you, or a disease you don’t have. The longevity market is passing off an approval built for one as proof of the other.

What the FDA actually approved

Tesamorelin, approved as Egrifta on November 10, 2010, carries a precise label: to reduce and maintain a reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy. Not aging adults, not belly fat in general: one named disease, in one named group of people.

That maintenance language is in the label because the extension phase showed what happens when you stop: patients re-randomized from tesamorelin to placebo lost the fat reduction over the following six months. This is a maintenance drug. Stop injecting, and the fat comes back.

It’s also the only GHRH-class peptide with a live FDA approval. Sermorelin had one once: Geref, approved for children with growth hormone deficiency, until its maker pulled it from the market in 2008 for commercial reasons. CJC-1295 never got one. Tesamorelin’s approval is current, and it rests on two Phase III trials, 816 people enrolled between them. The 15.2% figure comes from the first, Falutz et al. 2007 in the New England Journal of Medicine, 412 people over 26 weeks. The second enrolled 404 people on the same 26-week design and found a smaller but still significant reduction. Both trials extended into a second six months for patients who stayed on the drug, and the effect held. Randomized, placebo-controlled, with pre-registered outcomes.

The chemistry holds up too. Tesamorelin is the body’s own growth-hormone-releasing hormone, all 44 amino acids of it, with one extra chemical tag on the end. Without that tag, the body destroys the molecule within minutes. The tag keeps it intact long enough to work. The molecule still clears fast; what lasts is the growth-hormone pulse each shot triggers, and one pulse a day is what the dosing is built on. That tag is drug engineering, not a compounding shortcut.

The current version, Egrifta WR, lets you mix a week’s supply at once instead of a fresh prep every morning. Bioequivalent to the original. A real drug with a real clinical record, for a disease the off-label market doesn’t have. The approval doesn’t answer their question. A much thinner file does.

The non-HIV trial: what it says and doesn’t

There is one randomized trial of tesamorelin in people with belly fat but no HIV. One. That trial enrolled only 60 people, and they had to pass a hormone screening most people wouldn’t qualify for. Visceral fat went down. So did carotid artery wall thickness and a key inflammation marker. A signal, and a genuinely interesting one. Not proof.

Sixty people is a pilot study. It can raise a hypothesis; it can’t confirm one. The effect may be real. A trial that small can’t tell you.

Longevity marketing cites Makimura next to Falutz as if the two add up to one body of evidence. They don’t. One is a 412-person Phase III for a named disease. The other is a 60-person pilot in a different, hormonally screened population. That’s an approval sitting next to a promising pilot that doesn’t quite touch it.

The chain from FDA approval to off-label confidence is exactly one 60-person trial long.

And visceral fat is only half the story. The claim gaining the most ground right now is about the brain. That evidence is even younger.

The cognition signal: real trial, open questions

Baker et al. 2012 (PMID 22869065) tested tesamorelin in 152 adults over 20 weeks, some with mild cognitive impairment, some healthy older adults. The cognition signal is real: executive function improved in both groups. And it came from tesamorelin, not sermorelin. That matters because marketing copy keeps crediting the wrong molecule.

The trial did follow people past the last injection: cognitive testing ran to week 30, ten weeks after the shots stopped. What it can’t tell you is anything beyond that. Whether the benefit holds at month six, or year two, is unmeasured. It builds on prior work from the same team, which is why researchers take it seriously, but no one has run the same experiment again to confirm it.

So the cognitive case rests on five months of dosing, a ten-week tail, and nothing after. In trial terms: interesting, not established.

Does a rising number in your bloodwork actually mean anything for your health?

Tesamorelin nudges your pituitary to release growth hormone in short natural bursts, not a constant flood. That’s the pitch for this whole class: work with your own system instead of replacing it.

More growth hormone means more IGF-1, a protein your liver makes in response. IGF-1 tracks with things the longevity crowd cares about: muscle, metabolic markers, maybe brain function. Both trials saw it rise.

But a rising number is not an outcome. Nobody has run the study that connects a rising IGF-1 level to a healthy 45-year-old actually getting healthier. Not over months, and certainly not over years of use. The mechanism is plausible. The outcome data doesn’t exist.

The safety file: who’s actually in it

Every safety number tesamorelin has comes from HIV lipodystrophy patients. People on antiretrovirals, with altered metabolism, carrying the exact fat disease the drug was approved for. The known side effects, fluid retention, joint pain, higher blood sugar, raised IGF-1 in people already at metabolic risk, were all logged in those bodies. Whether a healthier body sees the same rates is a gap in the file, not speculation.

WADA bans tesamorelin outright, the way it bans anything that moves growth signals this hard. And separately from the ban, nobody has formally tracked what happens to healthy people using it outside a trial.

The safety record is real. It just belongs to a different population. The blood tests, the adverse-event tallies, the monitoring protocols: all of it was built around HIV patients, not the person drawing up a vial from their home fridge.

Where the evidence actually stops

Tesamorelin’s own file is the argument against the stretch, not against the drug.

Two Phase IIIs proved it works for HIV lipodystrophy. Makimura is 60 people. Baker is 152, never replicated with tesamorelin. That’s the whole shape of the evidence. Anyone selling the other GHRH peptides would trade everything for that file, and even that file stops well short of what’s being claimed.

The claims keep spreading anyway. A 2026 review in Sports Medicine (Mendias and Awan) now covers tesamorelin alongside sermorelin and CJC-1295, and reads less like a longevity endorsement than a warning about the gray market carrying them.

Closing the gap takes one thing: a properly designed trial, real participants, a dummy-pill comparison group, and the key health outcomes decided before anyone looks at the data, in the people most likely to use it. That trial doesn’t exist.

Administration

Tesamorelin goes under the skin once a day, into the fat of the abdomen. Egrifta WR lets you mix a week’s supply at once; compounded versions mean a fresh prep each time. The schedule isn’t optional: each shot triggers one growth-hormone pulse, and the daily pulse is the therapy.

What the evidence gives you today

The 15.2% visceral fat reduction is real, measured in people with a disease you almost certainly don’t have, and reversible the day they stopped. The Makimura signal is real but too small to confirm anything about your body. Baker’s cognition finding is real and stops at week 30.

What the file gives you is the strongest pedigree in the peptide space: proof the molecule does something meaningful, reviewed seriously by the FDA. What it doesn’t give you is a trial that enrolled someone like you, in your metabolic state, over the time horizon you’re planning. The step from the approval to your abdomen is a hypothesis. A serious one. Not a confirmed outcome.

The trial that hasn’t been run

Tesamorelin’s approval was built to prove one thing, for one disease, and it did. The Phase IIIs are clean. And because the file is real, you can read exactly where the proof ends, something you can’t do with the peptides that never had a trial at all.

The next move is the trial in the adults actually using the drug, not more extrapolation from the existing file. It would either confirm the hypothesis or show the fat signal is disease-specific and doesn’t travel. Either answer is worth having. Some compound in this class will clear that bar eventually. Whether it’s tesamorelin, the one that already has the file, is the thing to watch.